Navigation Links
Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2008 Financial Results and to Host Conference Call and Webcast on Thursday, March 12, 2009
Date:3/5/2009

SAN DIEGO, March 5 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report fourth quarter and full year 2008 financial results after the NASDAQ Global Market closes on Thursday, March 12, 2009. That same afternoon, Jack Lief, Arena's President and Chief Executive Officer, and Robert E. Hoffman, Arena's Vice President, Finance and Chief Financial Officer, will host a conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the financial results for the fourth quarter and full year 2008 and to provide a financial update.

The conference call may be accessed by dialing 877.741.4240 for domestic callers and 719.325.4753 for international callers. Please specify to the operator that you would like to join the "Arena Pharmaceuticals Fourth Quarter 2008 Earnings Call." The conference call will be webcast live under the investor relations section of Arena's website at www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Mer
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist
2. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
3. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
4. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
5. Arena Pharmaceuticals to Present at the Piper Jaffray 20th Annual Health Care Conference
6. Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
7. Childrens Miracle Network and Arena Football League Partner for First Nationwide Celebration Event
8. Field Poll: California Nurses Association Most Favorably Viewed Group in Healthcare Arena
9. Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008
10. Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
11. Arena Pharmaceuticals Lorcaserin for Obesity Passes Major Safety Milestone

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)...of the Live Life Again Center, a practice offering...ing number of physicians who are taking advantage...h individuals who are interested in surgical weigh...is utilizing Facebook to share before-and-after ph...ommunity. , Dallas, TX (V...
(Date:11/25/2009).../--TheBartleHallConventionCenterwilltemporarilybec...ansasCityhoststhelatestinaseriesofmassivefreeclini...sthepotentialtobethebiggestoneyet,becauseitwillext...nsteadofoveraweekend,"SheriWood,executivedirectoro...ionalAssociationofFreeClinics(NAFC). ,, Atprevi...
(Date:11/25/2009)...re-USNewswire/--AnarticlebyJanetWoodcock,M.D.,dire...itled"ADifficultBalance-PainManagement,DrugSafety,...landJournalofMedicine. ,, (Logo: http://www.new...hearticle,WoodcockdiscussesFDAeffortstostrikeabala...ndmanagingtherisksposedbyvariousanalgesics.Asexamp...
(Date:11/25/2009)...tatistically significant survival benefit from adj...ptor (ER)-positive tumors had high levels of phosp...18-P), according to a brief communication publishe...al Cancer Institute . , Approximately 50% of bre...ical studies have shown that ER-alpha S118-P is re...
(Date:11/25/2009)... treatment clinics to resume Monday, Nov. 30 , ...5, 2009 -- Centegra Health System is continuing to...at four Centegra Primary Care (CPC) vaccination cl...d. The clinics are at CPC sites in Huntley, Woodst...follows: ,   From 4:30 to 7:30 p.m. Tu...
Breaking Medicine News(10 mins):Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3Health News:Kansas City Prepares for Largest Free Health Clinic 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4
...echniques of soft condensed matter physics, a rese...finely tuned balance of attractions between protei... even a small change in this balance can cause pro...gregation diseases (such as Alzheimers disease), a...
...007) New research published in the November issue...s shows that urban colorectal and lung cancer pati... patients do. This finding is contrary to the com...nts presenting with metastatic cancer is alarming,...
... 9 Hooper Holmes,Inc. (Amex: HH ), a leading pro...unced financial results for the third quarter ende...were $56.3 million compared to $60.6,million in th... loss of $42.1 million or $(0.63) per share in the...
... Pharmaceutical product teams,have the power to m...lem is,launch teams often lack the right structure...fore only produce a sub-optimal launch. In fact, ...ialization. According to a study by pharmaceutical...
...y Distributing over 12 Million Narcotic Pain,Pills...ney Matt M. Dummermuth announced today that six me...istribute controlled substances through an,Interne... Rapids. The indictment also seeks forfeiture of m...
...now be mapped less to mathematical standards and m...y by researchers at Harvard and Johns Hopkins Univ...onal Biology on November 9, 2007, provides a new p...cancer has long been based on streamlined models w...
Other Medicine News:Health News:Physics provides new insights on cataract formation 2Health News:Study reveals differences in cancer stage presentation between rural and urban patients 2Health News:Hooper Holmes Announces Third Quarter 2007 Results 2Health News:Hooper Holmes Announces Third Quarter 2007 Results 3Health News:Hooper Holmes Announces Third Quarter 2007 Results 4Health News:Hooper Holmes Announces Third Quarter 2007 Results 5Health News:Hooper Holmes Announces Third Quarter 2007 Results 6Health News:Hooper Holmes Announces Third Quarter 2007 Results 7Health News:Pharmaceutical Product Commercialization: Enabling Teams to Excel 2Health News:Pharmaceutical Product Commercialization: Enabling Teams to Excel 3Health News:$40 Million Forfeiture Sought in Nation-Wide Internet Pharmacy Case 2
(Date:11/25/2009)...wswire/-- ChemoCentryx,Inc.,announcedtodaythatPha...rospectiveRandomizedOralTherapyEvaluationinCrohn,s...withmoderate-to-severeCrohn,sdiseasedemonstratedcl...rofile.Thestudydemonstratedevidenceofclinicaleffic...ointdecreaseintheCrohn,sDiseaseActivityIndex(CDAI)...
(Date:11/24/2009)...-FirstCall/--Endologix,Inc.(Nasdaq: ELGX ),develop...announcedtodaythatithasfiledamotiontostay,ordiscon...broughtagainstitinOctober2009byCook,Inc.Themotionw...s,Indiana. ,, Endologixhasrequestedthatthestayr...kOffice(USPTO)conductsproceedingstore-examinethetw...
(Date:11/24/2009)...tCall/--AnadysPharmaceuticals,Inc.(Nasdaq: ANDS )a...JaffrayHealthcareConferenceonTuesday,December1,200...ldatTheNewYorkPalaceHotel.SteveWorland,Ph.D.,Presi...overviewofAnadysanditsclinicaldevelopmentprograms,...lbesimultaneouslywebcastandcanbeaccessedontheInves...
Breaking Medicine Technology:ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2Patient Centered Primary Care Collaborative Stakeholders Come to Washington DC for July Working Meeting 49072 1Patient Centered Primary Care Collaborative Stakeholders Come to Washington DC for July Working Meeting 49072 2Patient Centered Primary Care Collaborative Stakeholders Come to Washington DC for July Working Meeting 49072 3Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara 28R 29 for the Treatment of Brain Cancer 12651 1Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara 28R 29 for the Treatment of Brain Cancer 12651 2Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara 28R 29 for the Treatment of Brain Cancer 12651 3Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara 28R 29 for the Treatment of Brain Cancer 12651 4Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara 28R 29 for the Treatment of Brain Cancer 12651 5Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara 28R 29 for the Treatment of Brain Cancer 12651 6Government of Canada supports research to help address medical isotope shortage 49067 1
...ears -- and works! Baby Gender Mentor Home DNA Gen...nology to attain the earliest gender detection wit...cy. The technique traces the amount of Y chromosom...Here's how it works: Your baby releases its DNA in...
...roducts, ,Westmed designs, manufacturers and mark... and Respiratory professionals. Our mission is to ...linician's ability to deliver quality medical care..., ,Our web site is designed with our customers in...
...mbrane glycoprotein associated with tyrosine kinas...ancer show an amplification and/or over-expression...on of Herceptin® as a targeted therapy for bre...reast carcinoma has become very important in patie...
...roducts, ,Westmed designs, manufacturers and mark... and Respiratory professionals. Our mission is to ...linician's ability to deliver quality medical care..., ,Our web site is designed with our customers in...
Medicine Products: